Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The deficits of insulin signal in Alzheimer’s disease and the mechanisms of vanadium compounds in curing AD

Version 1 : Received: 20 July 2023 / Approved: 21 July 2023 / Online: 21 July 2023 (11:30:52 CEST)

A peer-reviewed article of this Preprint also exists.

Yao, J.; He, Z.; You, G.; Liu, Q.; Li, N. The Deficits of Insulin Signal in Alzheimer’s Disease and the Mechanisms of Vanadium Compounds in Curing AD. Curr. Issues Mol. Biol. 2023, 45, 6365-6382. Yao, J.; He, Z.; You, G.; Liu, Q.; Li, N. The Deficits of Insulin Signal in Alzheimer’s Disease and the Mechanisms of Vanadium Compounds in Curing AD. Curr. Issues Mol. Biol. 2023, 45, 6365-6382.

Abstract

Vanadium is a well-known essential trace element, which usually exists in oxidation states in form of vanadate cation intracellularly. The pharmacological study of vanadium begins at the discovery of its unexpected inhibitory effect on ATPase. Thereafter, the protective effects on cells and the abilities in glucose metabolism regulation were observed from vanadium compound, leading to the application of vanadium compounds in clinical trials for curing diabetes. Alzheimer’s dis-ease (AD) is the most common dementia disease in elderly people. However, there is still no efficient agents for treating AD safely to date. This is mainly because of the complexity of the pathology, which are characterized by the senile plaques composed by amyloid-beta (Aβ) protein in the parenchyma of brain and the neurofibrillary tangles (NFTs) derived from hyperphosphorylated tau protein in neurocyte, along with mitochondrial damage, and eventually the central nervous system (CNS) atrophy. AD was also illustrated as type-3 diabetes, because of the observations of insulin deficiency and the high level of glucose in cerebrospinal fluid (CSF), as well as the im-paired insulin signaling in brain. In this review, we summarized the advance of applicating vanadium compound on AD treatment in experimental research and pointed out the limitation of the current study on using vanadium compounds in AD treatment. We hope it will help the future study in this field.

Keywords

Vanadium; Alzheimer’s disease; diabetes; insulin resistance; mitochondrial; oxidative phosphorylation

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.